|
課程名稱 |
疫苗：對抗下一場大流行的工具
The Role of Vaccines in Combating the Next Pandemic |
|
開課學期 |
112-2 |
|
授課對象 |
公共衛生學院 全球衛生博士學位學程 |
|
授課教師 |
黃婉婷 |
|
課號 |
MGH7051 |
|
課程識別碼 |
853EM0510 |
|
班次 |
|
|
學分 |
2.0 |
|
全/半年 |
半年 |
|
必/選修 |
選修 |
|
上課時間 |
星期二8,9(15:30~17:20) |
|
上課地點 |
公衛210 |
|
備註 |
本課程以英語授課。歡迎具流行病學基礎之研究生及大學部高年級生選修。與林先和、吳亞克合授
總人數上限：20人 |
|
|
|
|
課程簡介影片 |
|
|
核心能力關聯 |
核心能力與課程規劃關聯圖 |
|
課程大綱
|
|
為確保您我的權利,請尊重智慧財產權及不得非法影印
|
|
課程概述 |
Infectious diseases of epidemic and pandemic potential require new and creativemeans for prevention and control. The current systems are not designed to rapidlyproduce a safe and effective vaccine to prevent and contain a pathogen currentlyunknown to cause human diseases (Disease X).
The goal of this course is to introduce students to the concepts of designing,developing, evaluating, and distributing a vaccine before and/or during a publichealth emergency such as a pandemic. Students will be divided into groups and assigned projects relevant to/between the lectures to complete a hypotheticalvaccine development, rollout, and monitoring plan. |
|
課程目標 |
At the end of the course, students should be able to:
1. Understand the role of vaccines in containing infectious diseases epidemics;
2. Describe the different types of vaccines and process of vaccine development/approval;
3. Be familiar with the challenges associated with vaccine development/approval and rollout during a public health emergency;
4. Appraise the tools used and systems in place to assess vaccines in clinical trials and postauthorization studies. |
|
課程要求 |
Students are strongly recommended to complete one introductory course in epidemiology (or equivalent), or obtain consent of the instructor, before taking this course. Students should:
1. Read and review the reading materials before and after the lecture(s);
2. Attend lectures and participate in class discussions;
3. Collaborate as a group on project assignment and submit an essay. |
|
預期每週課後學習時數 |
Four (4) hours |
|
Office Hours |
另約時間 備註： Students can email the course instructor (Dr Wan-Ting Huang, huangwt@g.ntu.edu.tw) and teaching assistant (Danielle Brister, r11853008@ntu.edu.tw) to schedule an in-person or virtual meeting. |
|
指定閱讀 |
1. Nelson KC, Williams CM, 2022. Infectious Disease Epidemiology: Theory andPractice, 3rd Edition. Burlington, MA: Jones & Bartlett Learning, LLC.
2. Plotkin SA, Orenstein W, Offit PA, Edwards KM, 2017. Plotkin's Vaccines, 7thEdition. Philadelphia, PA: Elsevier.
3. Hahne S, Bollaerts K, Farrington P, 2022. Vaccination Programmes:Epidemiology, Monitoring, Evaluation, 1st Edition. New York, NY: Routledge. |
|
參考書目 |
1. Simpson S, Kaufmann MC, Glozman V, Chakrabati A. Disease X: accelerating the development of medical countermeasures for the next pandemic. Lancet Infect Dis 2020;20:e108–e115.
2. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med 2021;27:591–600.
3. Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 2010;28:2806–2809.
4. Nguyen TT, Chiu CH, Lin CY, Chiu NC, Chen PY, Le TTV, Le DN, Duong AH,Nguyen VL, Huynh TN, Truong HK, Phan TL, Nguyen TTT, Shih SR, Huang CG,Weng YJ, Hsieh EF, Chang S, Chen C, Tai IC, Huang LM. Efficacy, safety, andimmunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants andchildren: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet 2022;399:1708–1717.
5. Yeh MJ. Solidarity in pandemics, mandatory vaccination, and public health ethics. Am J Pub Health 2022;112:255–261. |
|
評量方式
(僅供參考) |
|
No. |
項目 |
百分比 |
說明 |
|
1. |
Participation |
30% |
Students are anticipated to actively participate in class lectures and discussions. |
2. |
Group project presentation |
40% |
Students will form groups of 3–5 members to develop their strategy foradvancing and evaluating their vaccine throughout the vaccine lifecycle. At least one of the members of each group will present and defend theirstrategy in class. |
3. |
Project assay |
30% |
Each group will submit a final project assay that is under 2,500 words based on their class presentations and discussions. |
|
|
針對學生困難提供學生調整方式 |
|
上課形式 |
以錄影輔助 |
|
作業繳交方式 |
團體報告取代個人報告 |
|
考試形式 |
書面(口頭)報告取代考試 |
|
其他 |
|
|
|
週次 |
日期 |
單元主題 |
|
第1週 |
2024-02-20 |
Welcome & introduction to the course
History of vaccines
Principles of vaccination
(WAN-TING HUANG) |
|
第2週 |
2024-02-27 |
Emerging infectious diseases in history
Disease X
(ANDREI AKHMETZHANOV) |
|
第3週 |
2024-03-05 |
Principles of infectious disease epidemiology
Disease burden and health needs (HSIEN-HO LIN) |
|
第4週 |
2024-03-12 |
Group project presentation (1):
Each group will select and present characteristics of their pathogen of interest and participate in a prioritization exercise |
|
第5週 |
2024-03-19 |
Priority pathogens
Considerations in vaccine development and approval
(WAN-TING HUANG) |
|
第6週 |
2024-03-26 |
Target product profile (TPP)
(WAN-TING HUANG) |
|
第7週 |
2024-04-02 |
Measurement of vaccine efficacy & safety
(WAN-TING HUANG) |
|
第8週 |
2024-04-09 |
Vaccine preparedness for public health emergencies
The 100 Days Mission
(WAN-TING HUANG) |
|
第9週 |
2024-04-16 |
Group project presentation (2):
Each group will develop and present their preferred vaccine construct & TPP, and appraise a synoptic clinical trial design |
|
第10週 |
TBC |
Unfinished work & midterm wrap-up (virtual)
(WAN-TING HUANG) |
|
第11週 |
2024-04-30 |
Vaccine rollout during public health emergencies
Ethical, legal, and social issues in vaccine responses
(WAN-TING HUANG) |
|
第12週 |
2024-05-07 |
Monitoring vaccination coverage
Measurement of vaccine effectiveness
(WAN-TING HUANG) |
|
第13週 |
2024-05-14 |
Field trip:
Vaccine cold chain, Zuellig Logistics Service, Dayuan, Taoyuan |
|
第14週 |
2024-05-21 |
Estimation of vaccination risk
Impact assessment of vaccination program
(WAN-TING HUANG) |
|
第15週 |
2024-05-28 |
Group project presentation (3):
Each group will propose and present a synoptic postapproval distribution, use, and follow-up plan for their vaccine |
|
第16週 |
TBC |
Review & final wrap-up (virtual)
(WAN-TING HUANG) |
|